Muthoot FinCorp Limited announces XVI Tranche IV series of NCDs, aims to raise Rs.360 crore

 

Muthoot FinCorp Limited (MFL or “Company”) the flagship company of 137-year-old Muthoot Pappachan Group (Muthoot Blue) has announced XVI Tranche IV series of secured, redeemable, non-convertible debentures (“NCDs”) to raise an amount aggregating to ₹360 crore which is within the shelf limit of ₹1100 crore. The tranche IV issuance amounts to ₹100 crore with a green shoe option of ₹260 crore aggregating up to ₹360 crore (“Tranche IV Issue”). The Tranche IV Issue with a face value of ₹1000 has been open to public from 10th April 2024 till 25th April 2024 subject to an early closure as may be approved by our Board of Directors or a duly constituted committee thereof of the Company, and subject to relevant approvals, in accordance with the Regulation 33A of the Securities and Exchange Board of India (Issue And Listing Of Non-Convertible Securities) Regulations, 2021. 

The NCDs under the Tranche IV Issue are being offered with maturity/tenure options of 26 months, 38 months, 60 months, 72 months and 94 months with monthly, annual, and cumulative payment options across different schemes - I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII and XIII from which the customers can conveniently choose. Effective yield (per annum) for the NCD holders in all categories of investors ranges from 8.90 percent to 10 percent. The secured NCDs issued under Tranche IV have been rated at AA-/ Stable by CRISIL and is proposed to be listed on the debt market segment of BSE. The funds will be used for onward lending, financing, and for repayment/ prepayment of interest and principal of existing borrowings of our Company and for the general corporate purposes. 

“Our previous series received positive response, and we hope to continue the momentum for this issue too. Customers can choose from the 13 different options in this Tranche and can invest through the 3600+ branches of MFL or via our mobile app Muthoot FinCorp ONE (upto Rs. 5lakhs). With the AA-/ Stable rating by CRISIL coupled with attractive interest rates and multiple tenure options we are focused on providing our investors with a suitable avenue to diversify their investment portfolio,” said Shaji Varghese, CEO – Muthoot FinCorp Limited.

 

Comments

Post a Comment

Popular posts from this blog

First DPL match was won by US Consulate Staff Team

Image
  ICWO - Indian Community Welfare Organisation  organized the First DPL- Diplomat Cricket Tournament for Embassy, Consulate & High Commission Staff on 10 th   August 2024 at Soka Ikeda College of Arts and Science for Women, Sethu Bhaskara Nagar, Madhanangkuppam, Kolathur, Chennai. T he event aims to create high level Awareness to STOP Child Abuse, Child Trafficking, Child Marriage & Child Labour in Tamilnadu and mobilize funds for intervention to address the same. A.J.Hariharan, Secretary – ICWO thanked both the US Consulate and Malaysian Consulate for their support and participation in the diplomate cricket tournament as to create an awareness about the Child Marriage, Child Trafficking & Child Labour and Child Abuse in Tamilnadu. The tournament has created huge interest among the players and the consul officials. We, ICWO have plan to organize similar event on 3 rd  May 2025. This time for men and women doubles badminton tournament. We emphasis there is...
Read more

TATA AIG Strengthens Tamil Nadu Health Insurance Portfolio with New Riders amid Strong Growth

Image
Chennai, 12 November 2024: TATA AIG General Insurance, a leading general insurance provider in India, is strengthening its health insurance offerings in Tamil Nadu with five specialised riders: Mental Wellbeing, Empower Her, OPD Care, CanCare, and Flexi Shield. These riders are specifically designed to address the unique and diverse healthcare needs of the state’s residents, providing enhanced protection in areas such as mental health, women’s health, cancer treatment, and routine medical costs. TATA AIG has established a robust presence across 31 districts in Tamil Nadu, with key branches in Chennai, Coimbatore, Madurai, Tiruchirapalli, Tirunelveli, and Salem. The company’s expansive network includes over 1000 hospitals, ensuring seamless access to cashless treatment for its customers across both urban and rural regions. With a well-established network of agents and digital platforms, the company is bringing quality health insurance solutions to every corner of the state. This pe...
Read more

Apollo Cancer Centers now introduces Made in India, CAR T Cell Program

Image
First Private Hospital in India to Successfully Complete CAR T Cell Therapy.  In a ground-breaking development, Apollo Cancer Centres (ACCs) has emerged as the first private hospital group in India to have a successfully complete CAR-T cell program and to further augment it, the group will now provide access to Made in India CAR-T cell therapy, beginning with NexCAR19 (Actalycabtagene autoleucel), for the treatment of B-cell lymphomas and B-acute lymphoblastic leukaemia in patients aged 15 years and above.   Marking a historic moment in the country's medical landscape , Dr. T Raja, Director of Medical Oncology at ACC, Chennai, spearheaded the development of this revolutionary clinical program, and has successfully treated six patients till date.   CAR-T cell therapies, often known as living drugs involve the extraction of a patients T-cells (a type of white blood cells whose function is to fight cancer cells) through a process known as Apheresis. These T-cells are t...
Read more